Skip to main content

Table 2 Baseline comorbidities

From: Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR)

 

Regular OCS use n = 223

Periodic OCS use n = 3054

No OCS use n = 12,160

P-value

Rhinitis, n (%)

34 (15.2)

660 (21.6)

2181 (17.9)

< 0.001

Nasal polyps, n (%)

11 (4.9)

147 (4.8)

231 (1.9)

< 0.001

Other acute lower respiratory infections, n (%)

60 (26.9)

938 (30.7)

2633 (21.7)

< 0.001

COPD, n (%)

62 (27.8)

423 (13.9)

999 (8.2)

< 0.001

Pneumonia, n (%)

47 (21.1)

527 (17.3)

1426 (11.7)

< 0.001

Diabetes type 2, n (%)

26 (11.7)

170 (5.6)

662 (5.4)

0.002

Hypertensive diseases, n (%)

88 (39.5)

696 (22.8)

2596 (21.3)

< 0.001

Ischaemic heart disease, n (%)

43 (19.3)

237 (7.8)

793 (6.5)

< 0.001

Heart failure, n (%)

35 (15.7)

160 (5.2)

425 (3.5)

< 0.001

Malignant neoplasm, n (%)

2 (0.9)

1 (0.0)

7 (0.1)

0.023

Cerebrovascular diseases, n (%)

17 (7.6)

70 (2.3)

297 (2.4)

< 0.001

Depression, n (%)

39 (17.5)

449 (14.7)

1623 (13.3)

0.042

Osteoporosis, n (%)

23 (10.3)

72 (2.4)

218 (1.8)

< 0.001